Overall market sentiment has been down on Halozyme Therapeutics, Inc. (HALO) stock lately. HALO receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.
Halozyme Therapeutics, Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on HALO!
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With HALO Stock Today?
Halozyme Therapeutics, Inc. (HALO) stock is up 2.54% while the S&P 500 has fallen -0.22% as of 11:55 AM on Tuesday, Sep 14. HALO is higher by $1.04 from the previous closing price of $40.98 on volume of 232,850 shares. Over the past year the S&P 500 has gained 31.79% while HALO is higher by 51.75%. HALO earned $1.56 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 26.88.
To see InvestorsObserver's Sentiment Score for Halozyme Therapeutics, Inc. click here.
More About Halozyme Therapeutics, Inc.
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Click Here to get the full Stock Report for Halozyme Therapeutics, Inc. stock.